Drug Profile


Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO 5541267; TECENTRIQ

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer ARCAGY/GINECO Group; Astex Pharmaceuticals; Chugai Pharmaceutical; Clovis Oncology; Columbia University; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Exelixis; Fondazione Michelangelo; Genentech; Gradalis; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; National Cancer Institute (USA); Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Preregistration Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Brain metastases; Chronic lymphocytic leukaemia; Gynaecological cancer; Soft tissue sarcoma; Solid tumours
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Pancreatic cancer
  • Phase I Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 02 Aug 2017 NICE invites Roche to submit a Cancer Drugs Fund proposal for atezolizumab in Urogenital cancer (Late-stage disease)
  • 24 Jul 2017 Genentech and Seattle Genetics agree to co-promote and co-develop SGN LIV1A in combination with atezolizumab in USA for Breast cancer
  • 24 Jul 2017 Genentech and Seattle Genetics plans the phase Ib/II MORPHEUS trial for Breast cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top